By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Drugs and Therapies. According to news reporting originating from Aurora, Colorado, by NewsRx correspondents, research stated, "Current standard of care for sustained back of the eye drug delivery is surgical placement or injection of large, slow release implants using a relatively large 22 gauge needle. We designed novel dipeptide (phenylalanine-alpha,beta,dehydrophenylalanine; Phe-Delta Phe) based nanotubes with a diameter of similar to 15-30 nm and a length of similar to 1500 nm that could be injected with a 33 gauge needle for sustained intravitreal delivery of pazopanib, a multi targeted tyrosine kinase inhibitor."
Our news editors obtained a quote from the research from the University of Colorado, "The drug could be loaded during nanotube assembly or post loaded after nanotube formation, with the former being more efficient at 25% w/w pazopanib loading and similar to 55% loading efficiency. Plain and peptide loaded nanotube were non-cytoloxic to retinal pigment epithelial cells even at a concentration of 200 mu g/ml. Following intravitreal injection of fluorescently labeled nanotubes using a 33 gauge needle in a rat model, the nanotube persistence and drug delivery were monitored using noninvasive fluorophotometry, electron microscopy and mass spectrometry analysis. Nanotubes persisted in the vitreous humor during the 15 days study and pazopanib levels in the vitreous humor, retina, and choroid-RPE at the end of the study were 4.5, 5, and 2.5-folds higher, respectively, compared to the plain drug."
According to the news editors, the research concluded: "Thus, Phe-Delta Phe nanotubes allow intravitreal injections with a small gauge needle and sustain drug delivery."
For more information on this research see: Self-assembled phenylalanine-alpha,beta-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor. Journal of Controlled Release, 2013;172(3):1151-1160. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
The news editors report that additional information may be obtained by contacting J.J. Panda, Univ Colorado Anschutz Med Campus, Dept. of Bioengn, Aurora, CO 80045, United States. Additional authors for this research include S. Yandrapu, R.S. Kadam, V.S. Chauhan and U.B. Kompella (see also Drugs and Therapies).
Keywords for this news article include: Aurora, Colorado, Proteins, Proteomics, United States, Phenylalanine, Tyrosine Kinase, Drugs and Therapies, Aromatic Amino Acids, Drug Delivery Systems, Enzymes and Coenzymes, Essential Amino Acids, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC